Antibodies in Preclinical & Clinical Studies
ichorbio is pleased to announce the release of our first list of all antibodies that are in discovery studies, preclinical and clinical trials. We're currently corresponding with as many biotech firms as we can to add their own candidates into this list. If you see that we're missing yours please contact us at hello@ichor.bio and we'll update our data immediately.
If you'd like to get this table as an Excel spreadsheet please click here.
| Target | Scientific Name | Companies Involved | Phase in Clinical Trials |
| 4-1BB | Urelumab | Bristol-Myers Squibb;National Cancer Institute (USA);Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University of Chicago;Medarex | Approved |
| 4-1BB | Utomilumab | Dana-Farber Cancer Institute;Immatics US;Kite Pharma;Kyowa Hakko Kirin;M. D. Anderson Cancer Center;Pfizer | Approved |
| a5b1 Integrin | Volociximab | Abbott Biotherapeutics Corp;Biogen Idec;IVERIC bio;National Cancer Institute (USA);PDL BioPharma | Discontinued |
| Activin A | Garetosmab | Regeneron | Phase 3 |
| ACVR2B | Bimagrumab | MorphoSys;Novartis | Approved |
| ACVRL1 | Ascrinvacumab | Duke University Medical Center;Fondazione IRCCS Istituto Nazionale dei Tumori;Pfizer;Suzhou Kintor Pharmaceuticals | Discontinued |
| ADCYAP1R1 | Zelminemab | Amgen | Approved |
| ADM | Enibarcimab | Adrenomed | Approved |
| ADPRC | Modakafusp | Takeda | Approved |
| ALCAM | Praluzatamab | CytomX Therapeutics;Immunogen | Approved |
| alpha toxin | Atidortoxumab | Adimab;Arsanis;X4 Pharmaceuticals | Discontinued |
| AMHR2 | Murlentamab | LFB Biotechnologies;GamaMabs Pharma | Approved |
| Amyloid | Anselamimab | Caelum Biosciences | Phase 3 |
| Amyloid | Birtamimab | Onclave Therapeutics Limited, subsidiary of Prothena | Phase 3 |
| Amyloid beta | Remternetug | Eli Lilly | Phase 3 |
| Angiopoietin 2 | Nesvacumab | Regeneron Pharmaceuticals;Sanofi | Discontinued |
| Angiopoietin-like 3 | Evinacumab | Regeneron Pharmaceuticals | Approved |
| ANGPT2 | Trebananib | Amgen | #N/A |
| ANGPT2 | Zansecimab | Eli Lilly | Discontinued |
| ANGPTL3 | Evinacumab | Regeneron Pharmaceuticals;Sanofi | Approved |
| anthrax protective antigen | Obiltoxaximab | Elusys Therapeutics | |
| AOC3 | Timolumab | Acorda Therapeutics;Biotie Therapies Corp.;Seikagaku Corporation | Discontinued |
| APCS | Dezamizumab | Pentraxin Therapeutics;GlaxoSmithKline | Discontinued |
| APP | Aducanumab | Biogen;Neurimmune | Approved |
| APP | Bapineuzumab | JANSSEN Alzheimer Immunotherapy;Pfizer;Wyeth;Elan Corporation | Discontinued |
| APP | Crenezumab | AC Immune;Genentech;Universidad de Antioquia | Approved |
| APP | Donanemab | Eli Lilly | Approved |
| APP | Gantenerumab | MorphoSys;Chugai Pharmaceutical;Roche | Approved |
| APP | Lecanemab | Biogen;Eisai | Approved |
| APP | Ponezumab | Rinat Neuroscience;Pfizer | Discontinued |
| APP | Solanezumab | Eli Lilly | Approved |
| APRIL | Sibeprenlimab | Otsuka Pharmaceutical | Phase 3 |
| APRIL | Zigakibart | Novartis / Chinook Therapeutics, Inc. | Phase 3 |
| AXL | Enapotamab | Genmab | Discontinued |
| Axl | Tilvestamab | BerGenBio | Approved |
| AXL receptor tyrosine kinase | Mecbotamab vedotin | BioAlta LLC | Phase 2 (potentially pivotal) |
| B. anthrasis PA | Raxibacumab | GlaxoSmithKline | Approved |
| B7-H3 | Vobramitamab duocarmazine | Macrogenics | Phase 2/3 |
| B7-H4 | Alsevalimab | Five Prime Therapeutics | Approved |
| BAFF | Belimumab | GlaxoSmithKline | Approved |
| BAFF Receptor | Ianalumab | MorphoSys | Phase 2/3 and Phase 3 |
| BCMA | Belantamab | GlaxoSmithKline | Approved |
| BCMA, CD3 | Elranatamab | Pfizer | Approved |
| BCMA, CD3 | Linvoseltamab | Regeneron | Phase 2 (potentially pivotal) |
| BCMA, CD3 | Teclistamab | Genmab;Janssen Research & Development | Approved |
| BDCA2 | Litifilimab | Biogen | Phase 2/3 and Phase 3 |
| Bet Pollen Antigen 1 | Bremzalerbart | Regeneron Pharmaceutical | Approved |
| Bet v 1 | Atisnolerbart | Regeneron | Approved |
| Bet v 1 | Umesolerbart | Regeneron | Approved |
| Bet v1 | Atisnolerbart, bremzalerbart, umesolerbart | Regeneron | Phase 3 |
| BK virus | AntiBKV | Memo Therapeutics AG | Phase 2/3 |
| BTLA | Tifcemalimab | Shanghai Junshi Biosciences | Approved |
| C. difficile exotoxin TcdB | Cocktail of biologics | Lumen Bioscience, Inc. | Phase 2/3 pending |
| C1q | ANX005 | Annexon Biosciences | Phase 3 |
| C1S | Riliprubart | TBC | Approved |
| C1s | Sutimlimab | Bioverativ;True North Therapeutics | |
| C5 | Crovalimab | Chugai Pharmaceutical;Roche | Approved |
| C5 | Gefurulimab | Alexion Pharmaceuticals, Inc. | Phase 3 |
| C5 | Olendalizumab | Alexion Pharmaceuticals | Discontinued |
| C5 | Pozelimab | Alnylam Pharmaceuticals;Regeneron Pharmaceuticals | Approved |
| C5 | Ravulizumab | Alexion Pharmaceuticals | Approved |
| C5 | Tesidolumab | MorphoSys;Novartis | Approved |
| C5 | Vensobafusp | TBC | Approved |
| C5 | Vilobelimab | InflaRX | Approved |
| C5AR1 | Avdoralimab | Novo Nordisk;Innate Pharma | Approved |
| CA125 | Oregovomab | Quest PharmaTech Inc. | Phase 3 |
| CA9 | Girentuximab | Centocor Inc;Heidelberg Pharma AG | Discontinued |
| CA9 | Iodine (124I) girentuximab | Centocor Inc;Heidelberg Pharma AG | #N/A |
| CALCA | Galcanezumab | Eli Lilly | |
| CALCA, CALCB | Eptinezumab | Alder Biopharmaceuticals | Approved |
| CCL2 | Carlumab | MorphoSys;Janssen Biotech | Discontinued |
| CCR2 | Plozalizumab | Millennium;Millennium Pharmaceuticals;Takeda;Takeda Oncology | Approved |
| CCR5 | Leronlimab | CytoDyn;Progenics Pharmaceuticals;The Scripps Research Institute | Approved |
| CD11 | Rovelizumab | ICOS Corporation | Discontinued |
| CD11a | Efalizumab | Genentech;Merck Serono;XOMA | |
| CD14 | Atibuclimab | ICOS Corporation;Implicit Bioscience | Approved |
| CD140a | Tovetumab | Cambridge Antibody Technology;MedImmune | Discontinued |
| CD147 | Metuzumab | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Phase 2/3 |
| CD158A | Lirilumab | Novo Nordisk;Bristol-Myers Squibb;Dana-Farber Cancer Institute;Innate Pharma;National Cancer Institute (USA);Ono Pharmaceutical;PrECOG;University of Texas M. D. Anderson Cancer Center | Approved |
| CD19 | Axicabtagene ciloleucel | Kite Pharma | #N/A |
| CD19 | Coltuximab ravtansine | ImmunoGen | Discontinued |
| CD19 | Denintuzumab mafodotin | Seattle Genetics | Phase 1/2 |
| CD19 | Duvortuxizumab | Janssen Biotech;MacroGenics | Discontinued |
| CD19 | Inebilizumab | Cellective Therapeutics;MedImmune | Approved |
| CD19 | Lisocabtagene maraleucel | Bristol-Myers Squibb;Juno Therapeutics | Approved |
| CD19 | Loncastuximab | ADC Therapeutics | Approved |
| CD19 | Tafasitamab | MorphoSys;The Ohio State University Comprehensive Cancer Center;Xencor | Approved |
| CD19 | Tisagenlecleucel | Novartis | Approved |
| CD19 | Vadacabtagene leraleucel | Bristol-Myers Squibb;Juno Therapeutics | Discontinued |
| CD19, Fc?RIIb | Obexelimab | Xencor | Phase 3 |
| CD194 | Mogamulizumab | Amgen;Bristol-Myers Squibb;Kagoshima University Dental School;Kyowa Hakko;Kyowa Hakko Kirin;Ono Pharmaceutical | Approved |
| CD2 | Alefacept | Astellas Pharma US, Inc., | Discontinued |
| CD20 | Ibritumomab tiuxetan | IDEC Pharmaceuticals | Approved |
| CD20 | Obinutuzumab | GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds | Approved |
| CD20 | Ocrelizumab | Genentech | Approved |
| CD20 | Ofatumumab | Novartis | Approved |
| CD20 | Rituximab | Biogen;Biogen Idec;Cedars-Sinai Medical Center;Chugai Pharmaceutical;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Janssen Research & Development;M. D. Anderson Cancer Center;Mayo Clinic;Nagoya University;Oregon Health & Science University;Roche;SCRI Development Innovations;Takeda Oncology;University of Gottingen;University of Texas M. D. Anderson Cancer Center;University of Tours;Zenyaku Kogyo | Approved |
| CD20 | Tositumomab-I131 | GlaxoSmithKline | Approved |
| CD20 | Veltuzumab | Immunomedics;Weill Cornell Medical College | Discontinued |
| CD20 | MIL62 | Beijing Mabworks Biotech Co., Ltd. | Phase 3 |
| CD20, CD3 | Epcoritamab | Genmab | Approved |
| CD200 | Samalizumab | Alexion Pharmaceuticals;The Leukemia & Lymphoma Society | Discontinued |
| CD22 | Inotuzumab | Alliance for Clinical Trials in Oncology;Cancer Research UK;Case Comprehensive Cancer Center;Children's Oncology Group;Erasmus MC;M. D. Anderson Cancer Center;National Cancer Institute (USA);Pfizer;SWOG;University College London;University of Texas M. D. Anderson Cancer Center;Celltech Group | Approved |
| CD22 | Moxetumomab pasudotox | AstraZeneca | Discontinued |
| CD22 | Pinatuzumab vedotin | Genentech;Roche | Discontinued |
| CD22 | Suciraslimab | Shenzhen Lonn Ryonn | Phase 3 |
| CD248 | Ontuxizumab | Ludwig Institute for Cancer Research;Morphotek;National Cancer Institute (USA) | Approved |
| CD25 | Camidanlumab | ADC Therapeutics;Genmab | Approved |
| CD25 | Daclizumab | AbbVie;Biogen;Dana-Farber Cancer Institute;National Cancer Institute (USA);PDL BioPharma | Approved |
| CD257 | Tabalumab | Eli Lilly | Discontinued |
| CD27 | Varlilumab | Celldex Therapeutics Inc;Oncothyreon;University of California at San Francisco;University of Virginia | Approved |
| CD274 | Bintrafusp alfa | Merck;GlaxoSmithKline | Discontinued |
| CD274 | Cosibelimab | Dana-Farber Cancer Institute;Checkpoint Therapeutics;TG Therapeutics Inc | Approved |
| CD274 | Envafolimab | Alphamab;3D Medicines;Sun Yat-Sen University | Approved |
| CD274 | Manelimab | Biocad | Discontinued |
| CD274 | Pacmilimab | CytomX Therapeutics | Approved |
| CD276 | Enoblituzumab | MacroGenics;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Approved |
| CD276 | Mirzotamab | AbbVie | Discontinued |
| CD276 | Omburtamab | Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics | Approved |
| CD279 | Penpulimab | Akeso Biopharma;Chia Tai Tianqing Pharmaceutical | Approved |
| CD28 | Lulizumab pegol | Bristol Myers Squibb | Phase 2 |
| CD3 | Muromonab- CD3 | Janssen-Cilag | Approved |
| CD30 | Brentuximab vedotin | Takeda | Approved |
| CD30 | Briakinumab | Cambridge Antibody Technology;Abbott GmbH & Co. KG | Discontinued |
| CD30 | Iratumumab | Medarex | Discontinued |
| CD326 | Edrecolomab | Ajinomoto;Centocor Inc | Discontinued |
| CD33 | Actinium (225Ac) lintuzumab satetraxetan | Actinium Pharmaceuticals | Phase 1 |
| CD33 | Gemtuzumab | UCB;Celgene Corporation;Pfizer;University of California San Diego | Approved |
| CD33 | Vadastuximab | Seattle Genetics | Discontinued |
| CD37 | Lilotomab | Nordic Nanovector | Approved |
| CD37 | Lutetium (177lu) lilotomab satetraxetan | Nordic Nanovector | Phase 1/2 |
| CD37 | Naratuximab | ImmunoGen;Chronic lymphocytic leukaemia | Approved |
| CD37 | Otlertuzumab | Trubion Pharmaceuticals;Aptevo Therapeutics | Discontinued |
| CD37 | Oxelumab | Genentech;Genmab;Roche | Discontinued |
| CD38 | Daratumumab | Boston Medical Center;Bristol-Myers Squibb;Dana-Farber Cancer Institute;French Innovative Leukemia Organisation;Genentech;Genmab;Janssen Biotech;Janssen Research & Development;M. D. Anderson Cancer Center;Syros Pharmaceuticals | Approved |
| CD38 | Felzartamab | MorphoSys AG | Phase 3 |
| CD38 | Felzartamab | MorphoSys | Approved |
| CD38 | Isatuximab | ImmunoGen;Huntsman Cancer Institute;Roche;Sanofi | Approved |
| CD38 | Mezagitamab | Takeda | Approved |
| CD3E | Cevostamab | Genentech | Approved |
| CD3E | Eluvixtamab | Amgen | Discontinued |
| CD3E | Emerfetamab | Amgen | Approved |
| CD3E | Flotetuzumab | MacroGenics;Servier | Discontinued |
| CD3E | Foralumab | Medarex;NovImmune SA;Harvard Medical School;Tiziana Life Sciences | Approved |
| CD3E | Obrindatamab | MacroGenics | Discontinued |
| CD3E | Otelixizumab | BTG;GlaxoSmithKline;Tolerx | Approved |
| CD3E | Pasotuxizumab | Amgen;Bayer HealthCare Pharmaceuticals;Micromet Inc | Discontinued |
| CD3E | Plamotamab | Xencor | Approved |
| CD3E | Solitomab | Micromet Inc;Amgen | Discontinued |
| CD3E | Tebentafusp | Immunocore;MedImmune | Approved |
| CD3E | Teplizumab | Immune Tolerance Network;MacroGenics;National Institute of Diabetes and Digestive and Kidney Diseases;National Institutes of Health (USA);Provention Bio;Tolerance Therapeutics | Approved |
| CD3E | Tepoditamab | Genmab;Janssen Research & Development | Discontinued |
| CD3E | Tidutamab | ICON;Xencor | Discontinued |
| CD3E | Vibecotamab | Xencor | Discontinued |
| CD3E/CD19 | Blinatumomab | Amgen;Astellas Pharma;M. D. Anderson Cancer Center;Merck & Co;Micromet Inc;National Cancer Institute (USA);University of California Davis | Approved |
| CD3E/CD20 | Glofitamab | Roche | Approved |
| CD3E/CD20 | Mosunetuzumab | Genentech | Approved |
| CD3E/CD20 | Odronextamab | Regeneron Pharmaceuticals | Approved |
| CD4 | Ibalizumab | Biogen Idec;TaiMed Biologics;Theratechnologies | |
| CD4 | Semzuvolimab | United Biopharma | Phase 3 |
| CD4 | Tregalizumab | Biotest AG | Discontinued |
| CD40 | Bleselumab | Kirin Brewery;Astellas Pharma;Kyowa Hakko Kirin | Discontinued |
| CD40 | Dacetuzumab | Seattle Genetics | Discontinued |
| CD40 | Giloralimab | AbbVie | Approved |
| CD40 | Iscalimab | Novartis;XOMA | Approved |
| CD40 | Lucatumumab | Novartis;XOMA | Discontinued |
| CD40 | Mitazalimab | Alligator Bioscience;Janssen Biotech | Approved |
| CD40 | Ravagalimab | AbbVie | Approved |
| CD40 | Selicrelumab | Abramson Cancer Center of the University of Pennsylvania;Roche | Discontinued |
| CD40 | Sotigalimab | Apexigen | Approved |
| CD40L | Dapirolizumab pegol | UCB | Phase 3 |
| CD40LG | Letolizumab | Bristol-Myers Squibb;H. Lee Moffitt Cancer Center and Research Institute | Approved |
| CD45 | Apamistamab-Iodine (131I) | Actinium Pharmaceuticals | Phase 3 |
| CD47 | Lemzoparlimab | I-Mab Biopharma Co. Ltd. | Phase 3 |
| CD47 | Letaplimab | Innovent Biologics | Approved |
| CD47 | Ligufalimab | Akeso Biopharma | Approved |
| CD47 | Magrolimab | Gilead Sciences | Phase 3 |
| CD47 | Ontorpacept | Pfizer | Phase 1/2 |
| CD47 | Urabrelimab | Surface Oncology | Discontinued |
| CD51 | Abituzumab | Merck | Approved |
| CD52 | Alemtuzumab | Bayer HealthCare Pharmaceuticals Inc.;Dana-Farber Cancer Institute;German CLL Study Group;Ohio State University Comprehensive Cancer Center;Sanofi;Sanofi Oncology;University of Cologne;University of Cambridge | Approved |
| CD52 | Gatralimab | Sanofi | Discontinued |
| CD6 | Itolizumab | Center of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium | Approved |
| CD62 | Crizanlizumab; crizanlizumab-tmca | Novartis | Approved |
| CD70 | Cusatuzumab | arGEN-X | Approved |
| CD70 | Vorsetuzumab | Seattle Genetics | Discontinued |
| CD73 | Mupadolimab | Corvus Pharmaceuticals | Approved |
| CD73 | Oleclumab | MedImmune;AstraZeneca;European Network of Gynaecological Oncological Trial Groups;Jules Bordet Institute | Approved |
| CD74 | Milatuzumab | Immunomedics | Discontinued |
| CD79b | Polatuzumab | Chugai Pharmaceutical;Genentech;Roche | Approved |
| CD80 | Belatacept | Bristol Myers Squibb | #N/A |
| CEA/CD3 | Cibisatamab | Roche | Approved |
| CEACAM5 | Cergutuzumab amunaleukin | Roche | Phase 1 |
| CEACAM5 | Labetuzumab govitecan | Immunomedics | Phase 1/2 |
| CEACAM5 | Tusamitamab | Sanofi-Aventis | Approved |
| CEACAM5 | Tusamitamab ravtansine | ImmunoGen | Phase 3 |
| CEACAM6 | Tinurilimab | Bayer;German Cancer Research Center | Discontinued |
| CFD | Lampalizumab | Tanox;Genentech | Discontinued |
| CGRP | Fremanezumab | Rinat Neuroscience;Teva Pharmaceutical Industries | Approved |
| CGRP receptor | Erenumab | Amgen;Novartis | |
| Claudin 18.2 | Zolbetuximab | Ganymed Pharmaceuticals | Approved |
| Clostridium difficile enterotoxin B | Bezlotoxumab | Medarex;University of Massachusetts Medical School;Merck & Co;Merck Sharp & Dohme | |
| CNR1 | Nimacimab | Bird Rock Bio | Approved |
| complement C3b, C4b | Mirococept | #N/A | #N/A |
| Complement protein C5 | Eculizumab | Alexion Pharmaceuticals;Brigham and Womens Hospital;Chiba University;Handok Inc | Approved |
| CSF-1R | Axatilimab | Syndax Pharmaceuticals, Inc | Phase 2 (pivotal) |
| CSF1 | Lacnotuzumab | Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Seoul National University Hospital | Approved |
| CSF1R | Cabiralizumab | Apexigen;Bristol-Myers Squibb;Five Prime Therapeutics;University of Chicago;Yale University | Approved |
| CSF1R | Emactuzumab | Roche;University of Texas M. D. Anderson Cancer Center | Approved |
| CSF2 | Gimsilumab | Ludwig Institute for Cancer Research;Morphotek | Discontinued |
| CSF2 | Lenzilumab | Humanigen;KaloBios Pharmaceuticals | Approved |
| CSF2 | Namilumab | Micromet Inc;Izana Bioscience;Takeda Pharmaceuticals International GmbH | Approved |
| CSF2 | Otilimab | GlaxoSmithKline;MorphoSys | Discontinued |
| CSF2RA | Mavrilimumab | Zenyth Therapeutics Kiniksa Pharmaceuticals;MedImmune | Approved |
| CSF2RB | Trabikibart | TBC | Approved |
| CSF3R | Anumigilimab | CSL Behring | Approved |
| CSF3R | Pegfilgrastim | #N/A | #N/A |
| CTGF | Pamrevlumab | FibroGen | Approved |
| CTLA-4 | Gotistobart | OncoC4, Inc | Phase 3 |
| CTLA-4 | Ipilimumab | Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Bavarian Nordic;Big Ten Cancer Research Consortium;BioGene Pharmaceutical;Bristol-Myers Squibb;Canadian Cancer Trials Group;Dana-Farber Cancer Institute;European Thoracic Oncology Platform;Grupo Espanol Multidisciplinar de Melanoma;Icahn School of Medicine at Mount Sinai;Intergroupe Francophone de Cancerologie Thoracique;Ludwig Institute for Cancer Research;Massachusetts General Hospital;Medarex;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National University Hospital (Singapore);Northwestern University;Olivia Newton-John Cancer Research Institute;OncoTherapy Science;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University College London;University of California at San Francisco;University of Texas M. D. Anderson Cancer Center | Approved |
| CTLA-4 | Nurulimab | Biocad | Phase 3 |
| CTLA-4 | Quavonlimab | Akeso Biopharma | Phase 3 |
| CTLA-4 | Tremelimumab | AIO Studien gGmbH;Amgen;ARCAGY/GINECO Group;AstraZeneca;Azienda Ospedaliera Universitaria Senese;Canadian Cancer Trials Group;Charite - Universitatsmedizin Berlin;Dana-Farber Cancer Institute;Fondazione IRCCS Istituto Nazionale dei Tumori;Grupo Espanol de Tumores Neuroendocrinos;Hoosier Cancer Research Network;Immunocore;Institute Gustave-Roussy;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);Northwestern University;Pfizer;Seoul National University Hospital;UNICANCER;University College London;University of Maryland Greenbaum Cancer Center;Yonsei University College of Medicine | Approved |
| CTLA-4 Fc Fusion Protein | Abatacept | #N/A | #N/A |
| CTLA4 | Zalifrelimab | 4-Antibody;Ludwig Institute for Cancer Research;Agenus;Recepta biopharma | Approved |
| CX3CL1 | Quetmolimab | KAN Research Institute;EA Pharma;Eisai Co Ltd | Approved |
| CXCL10 | Eldelumab | Bristol-Myers Squibb;Medarex | Discontinued |
| CXCR4 | Ulocuplumab | Bristol-Myers Squibb;Medarex;University of Bari | Approved |
| Dabigatran | Idarucizumab | Boehringer Ingelheim | Approved |
| DKK1 | Sirexatamab | Leap Therapeutics | Approved |
| DLL3 | Rovalpituzumab | Bristol-Myers Squibb;Stemcentrx | Discontinued |
| DLL3, CD3 | Tarlatamab | Amgen | Phase 2 (potentially pivotal) |
| DLL4 | Demcizumab | Celgene Corporation;OncoMed Pharmaceuticals | Discontinued |
| DLL4 | Enoticumab | Regeneron Pharmaceuticals;Sanofi | Discontinued |
| DLL4, VEGF | Navicixizumab | OncXerna Theraputics, Inc. | Phase 3 pending |
| DLL4, VEGF | National OncoVenture | Phase 2/3 | |
| DNA/histone | Iodine (131I) derlotuximab biotin | #N/A | #N/A |
| DPEP3 | Tamrintamab | Stemcentrx | Approved |
| DPP4 | Begelomab | ADIENNE | Approved |
| DR5 | Ozekibart | Inhibrx, Inc. | Phase 2 (pivotal) |
| Ebola virus | Ansuvimab-zykl | Approved | |
| EDNRA | Patecibart | TBC | Approved |
| EGFL7 | Parsatuzumab | Chugai Pharmaceutical;Genentech | Discontinued |
| EGFR | Amivantamab | Genmab;Janssen Research & Development | Approved |
| EGFR | Cetuximab | Array BioPharma;Bristol-Myers Squibb;Celldex Therapeutics Inc;Centre Jean Perrin;Eli Lilly;Merck KGaA;New York University School of Medicine;Novartis;Pierre Fabre;Roche;University Hospital Ghent;University of California;University of Heidelberg;University of Michigan Comprehensive Cancer Center | Approved |
| EGFR | Cetuximab sarotalocan | #N/A | #N/A |
| EGFR | Demupitamab | Sinocelltech | Approved |
| EGFR | Depatuxizumab | Ludwig Institute for Cancer Research;AbbVie | Discontinued |
| EGFR | Futuximab | Symphogen;Merck | Approved |
| EGFR | Imgatuzumab | GLYCART Biotechnology;Roche | Discontinued |
| EGFR | Laprituximab | ImmunoGen | Discontinued |
| EGFR | Losatuxizumab | AbbVie | Discontinued |
| EGFR | Modotuximab | Symphogen;Merck | Approved |
| EGFR | Necitumumab | ImClone Systems;Eli Lilly | Approved |
| EGFR | Nimotuzumab | Biocon Biopharmaceuticals;Biotech Pharmaceutical;Center of Molecular Immunology;CIMYM;Daiichi Sankyo Inc;Eurofarma;Gilead Sciences;Innogene Kalbiotech;InnoMab;Kuhnil Pharmaceutical Company;Laboratorios Pisa;Oncoscience | Approved |
| EGFR | Panitumumab | Approved | |
| EGFR | Petosemtamab | Merus | Discontinued |
| EGFR | Serclutamab | AbbVie | Discontinued |
| EGFR | Tomuzotuximab | Glycotope | Approved |
| EGFR | Shanghai Miracogen Inc. | Phase 3 | |
| EGFR, HER3 | Izalontamab | Biokin | Phase 2/3 |
| endogenous retrovirus | Temelimab | GeNeuro | Approved |
| ENG | Carotuximab | National Cancer Institute (USA);Santen Pharmaceutical;TRACON Pharmaceuticals;University of Alabama at Birmingham;University of Minnesota;Roswell Park Cancer Institute | Discontinued |
| ENTPD1 | Perenostobart | Surface Oncology;Arcus Biosciences | Approved |
| Enzyme substitute | Asfotase alfa | #N/A | #N/A |
| EPCAM | Citatuzumab bogatox | #N/A | #N/A |
| EPCAM | Oportuzumab monatox | #N/A | #N/A |
| EPCAM/CD3 | Catumaxomab | Approved | |
| EPHA3 | Ifabotuzumab | Ludwig Institute for Cancer Research;Humanigen;Olivia Newton-John Cancer Research Institute | Approved |
| ERA | Docaravimab | Candila Healthcare | Approved |
| ERA | Miromavimab | Candila Healthcare | |
| ERBB2 | Cinrebafusp | Eli Lilly | Approved |
| ERBB2 | Cinrebafusp alfa | #N/A | #N/A |
| ERBB2 | Disitamab | Yantai Rongchang Biological Engineering | Approved |
| ERBB2 | Gancotamab | Merrimack Pharmaceuticals;HERMES BioSciences | Discontinued |
| ERBB2 | Timigutuzumab | Roche | |
| ERBB2 | Trastuzumab deruxtecan | #N/A | |
| ERBB2 | Trastuzumab duocarmazine | #N/A | |
| ERBB2 | Trastuzumab emtansine | #N/A | |
| ERBB2 | Zanidatamab | Zymeworks | Approved |
| ERBB2 | Zenocutuzumab | Merus | Approved |
| ERBB3 | Duligotuzumab | Genentech;Roche | Discontinued |
| ERBB3 | Elgemtumab | MorphoSys;Novartis;Memorial Sloan-Kettering Cancer Center;Novartis Oncology | Discontinued |
| ERBB3 | Lumretuzumab | Roche | Discontinued |
| ERBB3 | Patritumab | Amgen;U3 Pharma;Daiichi Sankyo Company | Approved |
| ERBB3 | Seribantumab | Merrimack Pharmaceuticals;Sanofi | Discontinued |
| EREG | Fepixnebart | Eli Lilly and Company | Approved |
| F11 | Osocimab | Bayer HealthCare | Discontinued |
| F3 | Tisotumab | Genmab;Seattle Genetics | Approved |
| F9xF10 | Emicizumab | Chugai Pharmaceutical;Roche | |
| Factor IXa, Factor X | Novo Nordisk A/S | Phase 3 | |
| Factor substitute | Albutrepenonacog alfa | #N/A | #N/A |
| Factor substitute | Dalcinonacog alfa | #N/A | #N/A |
| Factor substitute | Oreptacog alfa | #N/A | #N/A |
| Factor XI | Abelacimab | Novartis | Phase 3 |
| Factor XIIa | Garadacimab | CSL Behring | Phase 3 |
| FAP | Simlukafusp alfa | #N/A | #N/A |
| FASLG | Asunercept | #N/A | #N/A |
| FCGRT | Batoclimab | Immunovant Sciences | Approved |
| FCGRT | Orilanolimab | Syntimmune | Discontinued |
| FCGRT | Rozanolixizumab | UCB | Approved |
| FcRn | Nipocalimab | Janssen | Phase 2/3 and Phase 3 |
| Fel d 1 | Freneslerbart | Regeneron Pharmaceuticals | Approved |
| Fel d 1 | Mevonlerbart | Regeneron | Approved |
| Felcat IL31 | Dovanvetmab | na | Approved |
| Felcat NGF | Frunevetmab | Nexvet | Approved |
| Felcat NGF | Relfovetmab | TBC | Approved |
| FGF23 | Burosumab | Kyowa Hakko Kirin;Ultragenyx Pharmaceutical | Approved |
| FGFR1 | Pegbelfermin | #N/A | #N/A |
| FGFR2 | Aprutumab ixadotin | #N/A | #N/A |
| FGFR2b | Aprutumab | Bayer | Discontinued |
| FGFR2b | Bemarituzumab | Amgen | Phase 3 |
| FGFR2b | Bemarituzumab | Five Prime Therapeutics;ZAI Lab | Approved |
| FGFR3 | Vofatamab | BioClin Therapeutics;Rainier Therapeutics | Approved |
| FGFR4 | Aldafermin | #N/A | #N/A |
| Fibronectin | Onfekafusp alfa | Philogen S.p.A. | Phase 3 |
| FLT1 | Icrucumab | ImClone Systems | Discontinued |
| FN | Bifikafusp alfa | #N/A | #N/A |
| FN | Radretumab | Philogen | Discontinued |
| Folate receptor alpha | Luveltamab tazevibulin | Sutro Biopharma | Phase 2/3 |
| FOLR1 | Farletuzumab | Ludwig Institute for Cancer Research;Morphotek;Eisai Co Ltd | Discontinued |
| FOLR1 | Mirvetuximab | ImmunoGen;National Comprehensive Cancer Network | Approved |
| frizzled family receptor | Vantictumab | Bayer HealthCare Pharmaceuticals;OncoMed Pharmaceuticals | Discontinued |
| FZD10 | Tabituximab | OncoTherapy Science;Centre Leon Berard | Discontinued |
| ganglioside GD2 | Dinutuximab | National Cancer Institute (USA);New Approaches to Neuroblastoma Therapy Consortium;St. John of God Foundation;United Therapeutics Corporation | Approved |
| ganglioside GD2 | Dinutuximab beta | #N/A | #N/A |
| Ganglioside GD2 | Naxitamab | Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics | Approved |
| GCGR | Crotedumab | Regeneron Pharmaceuticals;Sanofi | Discontinued |
| GCGR | Volagidemab | Amgen;REMD Biotherapeutics | Approved |
| GDF11 | Luspatercept | #N/A | #N/A |
| GDF15 | Ponsegromab | Pfizer | Discontinued |
| GDF15 | Visugromab | CatalYm | Approved |
| GDF2 | Dalantercept | #N/A | #N/A |
| GFRA3 | Nadecnemab | Regeneron Pharmaceuticals | Approved |
| GLP-1R | Gmax Biopharm Australia Pty Ltd | Phase 3 | |
| GLP1R | Albiglutide | #N/A | #N/A |
| GLP1R | Dulaglutide | #N/A | #N/A |
| Glycoprotein VI | Glenzocimab | Acticor Biotech | Phase 2/3 |
| GPC3 | Codrituzumab | Perseus Proteomics;Chugai Pharmaceutical;Roche | Approved |
| GPIIb/IIIa | Abciximab | Approved | |
| GPNMB | Glembatumumab | CuraGen Corporation;Celldex Therapeutics Inc;National Cancer Institute (USA) | Discontinued |
| GPRC5D, CD3 | Talquetamab | Genmab;Janssen Research & Development | Approved |
| GREM1 | Ginisortamab | UCB | Approved |
| GUCY2C | Indusatumab | Millennium;Takeda Oncology | Discontinued |
| HAVCR2 | Cobolimab | AnaptysBio;GlaxoSmithKline;TESARO | Approved |
| HBV | Lenvervimab | Green Cross;GC Pharma;AbbVie | Approved |
| heat shock protein 90 homolog | Efungumab | NeuTec Pharma | Discontinued |
| HER2 | [fam-]trastuzumab deruxtecan, fam-trastuzumab deruxtecan-nxki | Approved | |
| HER2 | Ado-trastuzumab emtansine | Approved | |
| HER2 | Anbenitamab | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2/3 (Phase 3 not yet recruiting) |
| HER2 | Anvatabart opadotin | Ambrx | Phase 2/3 |
| HER2 | Margetuximab | Raven biotechnologies;GC Pharma;Green Cross;MacroGenics;Merck Sharp & Dohme | Approved |
| HER2 | Pertuzumab | Chugai Pharmaceutical;Dana-Farber Cancer Institute;FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO;Genentech;International Breast Cancer Study Group;Japan Breast Cancer Research Group;Medica Scientia Innovation Research;Roche;West German Study Group | Approved |
| HER2 | Trastuzumab | Roche | |
| HER2 | Trastuzumab botidotin | Kelun-Biotech, subsidiary Klus Pharma | Phase 2 (pivotal) and phase 3 |
| HER2 | Trastuzumab duocarmazine | Approved | |
| HER2 | Trastuzumab rezetecan | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| HER2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 pending | |
| HER2 | LegoChem Biosciences, Inc. | Phase 3 | |
| HER2 | Shanghai Miracogen Inc. | Phase 2/3 | |
| HER2 | SUNHO（China）BioPharmaceutical CO., Ltd. or Beijing Sunho Pharmaceutical Co. | Phase 2/3 pending | |
| HGF | Ficlatuzumab | AVEO Oncology;AVEO Pharmaceuticals;Dana-Farber Cancer Institute;University of Arizona Cancer Center;University of California at San Francisco | Approved |
| HGF | Rilotumumab | Amgen;Astellas Pharma | Discontinued |
| HIV-1 | Alvircept sudotox | #N/A | #N/A |
| HIV-1 | Elipovimab | Gilead Sciences | Discontinued |
| HIV-1 | Suvizumab | Kaketsuken;Kumamoto University;University of Missouri-Columbia | Discontinued |
| ICAM1 | Bersanlimab | BioInvent International | Discontinued |
| ICOS | Feladilimab | GlaxoSmithKline | Approved |
| ICOS | Vopratelimab | Jounce Therapeutics | Approved |
| ICOSLG | Prezalumab | Amgen;MedImmune | Discontinued |
| ICOSLG | Rozibafusp alfa | #N/A | #N/A |
| idiotope of anti- | Racotumomab | Center of Molecular Immunology;Elea;Innogene Kalbiotech;Recombio | Approved |
| IFN-gamma | Emapalumab | NovImmune SA;Swedish Orphan Biovitrum | |
| IFN-β | Dazukibart | Pfizer Inc. | Phase 3 |
| IFNA1 | Bifarcept | #N/A | #N/A |
| IFNA1 | Rontalizumab | Chugai Pharmaceutical;Genentech | Discontinued |
| IFNA1 | Sifalimumab | Medarex;MedImmune | Discontinued |
| IFNAR1 | Albinterferon alfa-2b | #N/A | #N/A |
| IFNAR1 | Anifrolumab | Medarex;Medical University of Vienna;MedImmune | Approved |
| IFNAR1 | Peginterferon alfacon-2 | #N/A | #N/A |
| IFNAR1 | Sampeginterferon beta-1a | #N/A | #N/A |
| IFNAR1_IFNAR2 | Interferon alfacon-1 | #N/A | #N/A |
| IgE | Ligelizumab | Tanox | Phase 3 |
| IgE | Omalizumab | Dana-Farber Cancer Institute;Genentech;John Hopkins University;Novartis | Approved |
| IGF-1R | Innovent Biologics, Inc | Phase 2/3 | |
| IGF-1R | Viridian Therapeutics, Inc. | Phase 2/3 | |
| IGF1R | Cixutumumab | Eli Lilly;ImClone Systems;M. D. Anderson Cancer Center;National Cancer Institute (USA) | Discontinued |
| IGF1R | Dalotuzumab | Pierre Fabre;Merck & Co | Discontinued |
| IGF1R | Figitumumab | Pfizer | Discontinued |
| IGF1R | Ganitumab | Amgen;Millennium;NantWorks;National Cancer Institute (USA);Novartis;Takeda;Takeda Oncology;UCLAs Jonsson Comprehensive Cancer Center | Discontinued |
| IGF1R | Istiratumab | Adimab;Merrimack Pharmaceuticals | Discontinued |
| IGF1R | Robatumumab | Merck & Co;Schering-Plough | Discontinued |
| IGF1R | Teprotumumab | Genmab;Roche;Horizon Therapeutics plc | Approved |
| IGF2 | Dusigitumab | MedImmune | Discontinued |
| IGF2 | Xentuzumab | Boehringer Ingelheim;Eli Lilly | Approved |
| IGHE | Quilizumab | Genentech | Discontinued |
| IL-12/23 | Ustekinumab | Approved | |
| IL-12/23p40 | Ebdarokimab | Akesobio Australia Pty Ltd | Phase 3 |
| IL-13 | Cendakimab | AbbVie | Phase 3 |
| IL-13 | Lebrikizumab | Chugai Pharmaceutical;Comprehensive Clinical Research Network;Dermira;Genentech;Roche;Tanox | Approved |
| IL-13 | Tralokinumab | Cambridge Antibody Technology;Icahn School of Medicine at Mount Sinai;LEO Pharma;MedImmune | Approved |
| IL-17 | Brodalumab | Amgen;AstraZeneca;Bausch Health Companies;Kyowa Hakko Kirin;LEO Pharma | Approved |
| IL-17A | Ixekizumab | Eli Lilly;Oregon Health & Science University;Torii Pharmaceutical | Approved |
| IL-17A | Vunakizumab | Atridia Pty Ltd./ Jiangsu Hengrui Medicine Co. | Phase 2/3 and Phase 3 |
| IL-17A | Xeligekimab | Genrix (Shanghai) Biopharmaceutical Co. Ltd. | Phase 3 |
| IL-17A | 3SBio | Phase 3 | |
| IL-1B | Gevokizumab | IRIS;National Eye Institute;North Shore-Long Island Jewish Health System;Novartis;Servier;University of Zurich;XOMA | Approved |
| IL-20 | Fletikumab | ZymoGenetics;Novo Nordisk | Discontinued |
| IL-22 | Fezakinumab | Pfizer;Wyeth | Discontinued |
| IL-23 | Guselkumab | Janssen Biotech;MorphoSys;Taiho Pharmaceutical | Approved |
| IL-23 p19 | Picankibart | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 |
| IL-2R | Basiliximab | Approved | |
| IL-31RA | Nemolizumab | Chugai Pharmaceutical;Galderma;Maruho | Approved |
| IL-33 | Etokimab | AnaptysBio | Discontinued |
| IL-33 | Itepekimab | Regeneron | Phase 3 |
| IL-33 | Tozorakimab | AstraZeneca/MedImmune | Phase 3 |
| IL-33R | Astegolimab | Hoffmann-La Roche | Phase 2/3 |
| IL-36R | Imsidolimab | AnaptysBio, Inc. | Phase 3 |
| IL-3R | Tagraxofusp | Stemline Therapeutics | Approved |
| IL-3RA | Pivekimab | ImmunoGen | Approved |
| IL-4R alpha | Dupilumab | Aimmune Therapeutics;Regeneron Pharmaceuticals;Sanofi | Approved |
| IL-4Rα | Keymed Biosciences Co. Ltd | Phase 3 | |
| IL-4Rα | Suzhou Connect Biopharmaceuticals, Ltd. | Phase 2 (pivotal) | |
| IL-5 | Depemokimab | GlaxoSmithKline | Phase 3 |
| IL-5 | Mepolizumab | Approved | |
| IL-6 | Clazakizumab | Alder Biopharmaceuticals;Cedars-Sinai Medical Center;Medical University of Vienna;Vitaeris | Approved |
| IL-6 | Olokizumab | R-Pharm;UCB | Approved |
| IL-6 | Siltuximab | Centocor Inc;Janssen Biotech;Memorial Sloan-Kettering Cancer Center | Approved |
| IL-6 | Hoffmann-La Roche | Phase 3 | |
| IL-6 receptor | Tocilizumab | Assistance Publique Hopitaux de Paris;Charite - Universitatsmedizin Berlin;Chugai Pharmaceutical;Hospital for Special Surgery;JW Pharmaceutical;Roche;University Hospital Inselspital;University Hospital;Osaka University Tubingen;University of Bern;University of Pittsburgh | Approved |
| IL-6R | Sarilumab | Asahi Kasei Pharma Corp;Regeneron Pharmaceuticals;Sanofi | Approved |
| IL-6R | Satralizumab | Chugai Pharmaceutical;Roche | |
| IL-7RA | Lusvertikimab | OSE Immunotherapeutics | Approved |
| IL-9 | Enokizumab | Genaera Corporation;Ludwig Institute for Cancer Research;MedImmune | Discontinued |
| IL12B | Ustekinumab | Centocor Inc;Janssen Biotech;Medarex | Approved |
| IL13 | Abrezekimab | UCB | Discontinued |
| IL13 | Anrukinzumab | Pfizer;Wyeth | Discontinued |
| IL13 | Cendakimab | Abbott Laboratories;AbbVie;Receptos | Approved |
| IL13 | Dectrekumab | Novartis | Discontinued |
| IL13RA1 | Eblasakimab | ASLAN Pharmaceuticals | Approved |
| IL15 | Inbakicept | #N/A | #N/A |
| IL15RA | Nogapendekin alfa | #N/A | #N/A |
| IL17A | Afasevikumab | NovImmune;Genentech | Discontinued |
| IL17A | Bimekizumab | UCB | Approved |
| IL17A | Netakimab | CJSC Biocad | Approved |
| IL17A | Perakizumab | Roche | Discontinued |
| IL17A | Secukinumab | Beth Israel Deaconess Medical Center;GWT-TUD GmbH;Icahn School of Medicine at Mount Sinai;Novartis;Alcon | Approved |
| IL17A | Sonelokimab | #N/A | #N/A |
| IL17A | Tibulizumab | Eli Lilly | Discontinued |
| IL1A | Bermekimab | XBiotech Inc. | Approved |
| IL1A | Vilamakitug | XBiotech USA, Inc | Approved |
| IL1B | Canakinumab | Charite - Universitatsmedizin Berlin;Novartis;Triemli hospital;University Hospital Tubingen;University Hospital Zurich | Approved |
| IL1B | Lutikizumab | Abbott Laboratories;AbbVie | Discontinued |
| IL1B | Rilonacept | #N/A | #N/A |
| IL1RAP | Nadunolimab | Lund University;Cantargia | Approved |
| IL1RL1 | Astegolimab | Amgen;Genentech;University of Leicester | Approved |
| IL1RL2 | Denileukin diftitox | #N/A | #N/A |
| IL2 | Aldesleukin | #N/A | #N/A |
| IL21 | Avizakimab | MedImmune;Boston Pharmaceuticals | Approved |
| IL23A | Brazikumab | Allergan;Amgen;AstraZeneca | Approved |
| IL23A | Mirikizumab | Eli Lilly | Approved |
| IL23A | Risankizumab | AbbVie;Boehringer Ingelheim | Approved |
| IL23A | Tildrakizumab | Almirall S.A.;Merck & Co;Schering-Plough;Sun Pharmaceutical Industries | Approved |
| IL2RB | Bempegaldesleukin | #N/A | #N/A |
| IL33 | Torudokimab | Eli Lilly | Approved |
| IL36RN | Spesolimab | Boehringer Ingelheim | Approved |
| IL3RA | Talacotuzumab | CSL;Janssen Biotech | Approved |
| IL4 | Romilkimab | Sanofi | Discontinued |
| IL4R | Manfidokimab | Akeso Biopharma | Approved |
| IL4R | Rademikibart | TBC | Approved |
| IL4R | Stapokibart | TBC | Approved |
| IL5 | Reslizumab | Celltech R&D;Schering-Plough;Allergy and Asthma Clinical Research;Celltech R&D;Teva Pharmaceutical Industries | Approved |
| IL5 | Varokibart | Teva Pharmaceutical | Approved |
| IL5RA | Benralizumab | AstraZeneca;Cincinnati Children's Hospital Medical Center;Kyowa Hakko;Kyowa Hakko Kirin;McMaster University;MedImmune;National Jewish Medical and Research Center;BioWa | Approved |
| IL6 | Olamkicept | #N/A | #N/A |
| IL6 | Sirukumab | Centocor Inc;GlaxoSmithKline;Janssen Biotech | Approved |
| IL6 | Ziltivekimab | AstraZeneca;Corvidia | Approved |
| IL6R | Levilimab | Biocad | Approved |
| IL6R | Vobarilizumab | Ablynx | Discontinued |
| influenza A virus hemagglutinin HA | Firivumab | Celltrion | Discontinued |
| influenza A virus hemagglutinin HA | Gedivumab | Genentech | Discontinued |
| influenza A virus hemagglutinin HA | Navivumab | Celltrion | Discontinued |
| influenza A virus hemagglutinin HA2 subunit from various strains | Diridavumab | National Institute of Allergy and Infectious Diseases;Crucell | Approved |
| influenza B virus hemagglutinin | Lesofavumab | Genentech | Discontinued |
| INHBA | Sotatercept | #N/A | #N/A |
| INSR | Valanafusp alfa | #N/A | #N/A |
| Interferon | Mipeginterferon alfa-2b | PharmaEssentia | Approved |
| ITGA2 | Vatelizumab | Chromos Molecular Systems;Glenmark Pharmaceuticals S.A.;Sanofi | Discontinued |
| ITGA2B_ITGB3 | Tadocizumab | PDL BioPharma;Yamanouchi | Discontinued |
| ITGA4 | Natalizumab | Biogen;Biogen Idec;Elan Corporation;Perrigo | Approved |
| ITGA4/ITGB7 | Abrilumab | Amgen;AstraZeneca | Discontinued |
| ITGA4/ITGB7 | Etrolizumab | Genentech;Roche | Approved |
| ITGAV_ITGB3 | Etaracizumab | Applied Molecular Evolution;MedImmune | Discontinued |
| ITGAV_ITGB3 | Intetumumab | Centocor Inc;Janssen Biotech;Janssen-Cilag | Discontinued |
| KDR | Alacizumab pegol | #N/A | #N/A |
| KDR | Olinvacimab | PharmAbcine;3SBio | Approved |
| KDR | Pegdinetanib | #N/A | #N/A |
| KIR3DL2 | Lacutamab | University of Genoa;Innate Pharma | Approved |
| KLKB1 | Lanadelumab | Dyax;Shire;Takeda | |
| KLRG1 | Ulviprubart | Abcuro, Inc. | Phase 2/3 |
| KLRK1 | Tesnatilimab | Janssen Research & Development | Approved |
| L-Selectin | Aselizumab | PDL Biopharma | Discontinued |
| LAG-3 | Favezelimab | Merck Sharp & Dohme Corp. | Phase 3 |
| LAG-3 | Fianlimab | Regeneron Pharmaceuticals | Phase 2/3 and Phase 3 |
| LAG-3 | Relatlimab | Approved | |
| LAG3 | Encelimab | Anaptys Bio;TESARO | Approved |
| LAG3 | Ieramilimab | Immutep Limited;Novartis | Approved |
| LAG3 | Miptenalimab | Boehringer Ingelheim | Approved |
| LAG3 | Relatlimab | Bristol-Myers Squibb;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Approved |
| LEPR | Mibavademab | Regeneron Pharmaceuticals | Approved |
| LGALS3 | Oloctinebart | TBC | Approved |
| LHCGR | Choriogonadotropin beta | #N/A | #N/A |
| LILRA4 | Daxdilimab | Viela Bio | Approved |
| LILRB2 | Polzastobart | Jounce Therapeutics | Approved |
| LILRB4 | Rolistobart | TBC | Approved |
| LINGO1 | Opicinumab | Biogen Idec;Dyax;Biogen | Discontinued |
| LOXL2 | Simtuzumab | Arresto Biosciences;Gilead Sciences | Discontinued |
| LRRC15 | Samrotamab | AbbVie | Approved |
| LRRC32 | Livmoniplimab | AbbVie | Approved |
| LTA | Baminercept | #N/A | #N/A |
| LTA | Pateclizumab | Genentech | Discontinued |
| LukGH | Berlimatoxumab | Adimab;Arsanis;X4 Pharmaceuticals | Discontinued |
| LYPD3 | Lupartumab | Bayer HealthCare | Discontinued |
| MADCAM1 | Ontamalimab | Pfizer;Takeda | Discontinued |
| MAG | Refanezumab | GlaxoSmithKline | Discontinued |
| MAPT | Bepranemab | UCB BioPharma | Approved |
| MAPT | Gosuranemab | Biogen;Bristol-Myers Squibb;iPierian | Discontinued |
| MAPT | Semorinemab | AC Immune;Genentech | Approved |
| MAPT | Tilavonemab | AbbVie;C2N Diagnostics | Approved |
| MAPT | Zagotenemab | Eli Lilly | Discontinued |
| MASP2 | Narsoplimab | Omeros | Approved |
| MCAM | Imaprelimab | Neotope Biosciences;Onclave Therapeutics;Prothena;Prothena Corporation | Discontinued |
| MET | Emibetuzumab | Eli Lilly | Approved |
| MET | Onartuzumab | Chugai Pharmaceutical;Genentech | Discontinued |
| MET | Telisotuzumab | Pierre Fabre;AbbVie | Discontinued |
| MIF | Imalumab | Cytokine PharmaSciences;Baxalta;Shire;Takeda | Discontinued |
| MMP9 | Andecaliximab | Gilead Sciences | Discontinued |
| mouse anti-idiotype monoclonal antibody | Abagovomab | Menarini | Discontinued |
| MPL | Romiplostim | #N/A | #N/A |
| MS4A1 | Ocaratuzumab | Applied Molecular Evolution;MENTRIK Biotech | Discontinued |
| MS4A1 | Ripertamab | Sinocelltech | Approved |
| MS4A1 | Ublituximab | LFB Biotechnologies;rEVO Biologics;Johns Hopkins University;TG Therapeutics Inc | Approved |
| MSLN | Amatuximab | Eisai Co Ltd;Morphotek;National Cancer Institute (USA) | Discontinued |
| MSLN | Anetumab corixetan | #N/A | #N/A |
| MSLN | Anetumab ravtansine | #N/A | #N/A |
| MST1R | Narnatumab | ImClone Systems;Eli Lilly;ImClone Systems | Discontinued |
| MSTN | Domagrozumab | Kennedy Krieger Institute;Pfizer | Discontinued |
| MSTN | Landogrozumab | Eli Lilly | Discontinued |
| MSTN | Ramatercept | #N/A | #N/A |
| MSTN | Taldefgrobep alfa | #N/A | #N/A |
| MSTN | Trevogrumab | Regeneron Pharmaceuticals;Sanofi | Approved |
| MUC1 | Clivatuzumab tetraxetan | #N/A | #N/A |
| MUC1 | Gatipotuzumab | NEMOD Biotherapeutics;Glycotope | Approved |
| MUC1 | Yttrium (90Y) clivatuzumab tetraxetan | #N/A | #N/A |
| MUC1 sialylated carbohydrate tumour-associated | Cantuzumab ravtansine | #N/A | #N/A |
| MUC16 | Sofituzumab vedotin | #N/A | #N/A |
| MUC5AC | Ensituximab | Neogenix Oncology;Duke University Medical Center;H. Lee Moffitt Cancer Center and Research Institute;Johns Hopkins Medical Institutions;Montefiore Medical Center;National Cancer Institute (USA);Precision Biologics;University of North Carolina;University of Texas Southwestern Medical Center;Yale University School of Medicine | Approved |
| Myostatin | Apitegromab | Scholar Rock | Phase 3 |
| Myostatin | Chugai | Phase 2/3 | |
| N/A | Bevifimod | #N/A | #N/A |
| NaPi2b | Upifitamab rilsodotin | Mersana Therapeutics | Phase 2 (pivotal) and phase 3 |
| NCAM1 | Lorvotuzumab mertansine | #N/A | #N/A |
| NGF | Fasinumab | Mitsubishi Tanabe Pharma Corporation;Regeneron Pharmaceuticals;Teva Pharmaceutical Industries;Sanofi | Approved |
| NGF | Fulranumab | Janssen Pharmaceuticals;Janssen Research & Development;Takeda;Amgen | Discontinued |
| NGF | Tanezumab | Rinat Neuroscience;Pfizer | Approved |
| NKG2A | Monalizumab | Innate Pharma;MedImmune;NCIC Clinical Trials Group;Novo Nordisk | Approved |
| NOTCH1 | Brontictuzumab | OncoMed Pharmaceuticals;University of Texas M. D. Anderson Cancer Center | Discontinued |
| NOTCH2 | Tarextumab | OncoMed Pharmaceuticals | Approved |
| NRP1 | Vesencumab | Genentech;Roche | Discontinued |
| NT5E | Uliledlimab | TRACON Pharmaceuticals;I-Mab Biopharma | Approved |
| OX40 | Ivuxolimab | Pfizer Inc. | Phase 3 |
| OX40 | Rocatinlimab | Kyowa Hakko Kirin | Phase 3 |
| oxLDL | Orticumab | Abcentra;BioInvent International;Genentech | Approved |
| PcrV protein type III secretion system | Gremubamab | MedImmune | Discontinued |
| PcrV protein type III secretion system | Rivabazumab | KaloBios Pharmaceuticals Inc | Discontinued |
| PCSK9 | Alirocumab | Regeneron Pharmaceuticals;Sanofi;University Hospital Inselspital | Approved |
| PCSK9 | Bococizumab | Halozyme Therapeutics;Pfizer | Discontinued |
| PCSK9 | Evolocumab | Amgen;Amgen Astellas BioPharma;University Hospital Inselspital | Approved |
| PCSK9 | Frovocimab | Eli Lilly | Approved |
| PCSK9 | Lerodalcibep | #N/A | #N/A |
| PCSK9 | Lodelcizumab | Novartis | Discontinued |
| PCSK9 | Ongericimab | Shanghai Junshi Biosciences | Approved |
| PCSK9 | Ralpancizumab | Pfizer | Discontinued |
| PCSK9 | Recaticimab | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| PCSK9 | Tafolecimab | Innovent Biologics | Approved |
| PD-1 | Acrixolimab | Y-Biologics | Approved |
| PD-1 | Balstilimab | Agenus;Ludwig Institute for Cancer Research | Approved |
| PD-1 | Budigalimab | AbbVie | Approved |
| PD-1 | Camrelizumab | Chinese PLA General Hospital;Hangzhou Cancer Hospital;Incyte Corporation;Jiangsu Hengrui Medicine Co.;Nanjing Medical University;Peking University People's Hospital;Sun Yat-Sen University | Approved |
| PD-1 | Cemiplimab | Inovio Pharmaceuticals;ISA Pharmaceuticals;Regeneron Pharmaceuticals;Sanofi;Sidney Kimmel Cancer Center;SillaJen Biotherapeutics;University of Texas M. D. Anderson Cancer Center | Approved |
| PD-1 | Cetrelimab | Janssen Research & Development, LLC | Phase 3 |
| PD-1 | Cetrelimab | Janssen Research & Development | Approved |
| PD-1 | Dostarlimab | AnaptysBio;European Network of Gynaecological Oncological Trial Groups;GlaxoSmithKline;TESARO | Approved |
| PD-1 | Enlonstobart | TBC | Approved |
| PD-1 | Ezabenlimab | Boehringer Ingelheim | Approved |
| PD-1 | Finotonlimab | Sinocelltech Ltd | Phase 2/3 and Phase 3 |
| PD-1 | Geptanolimab | Genor Biopharma Co., Ltd. | Phase 2 (pivotal) |
| PD-1 | Iparomlimab | Qilu Pharmaceutical Co., Ltd. | Phase 2/3 |
| PD-1 | Lipustobart | Livzon Pharmaceutical Group | Approved |
| PD-1 | Lodapolimab | Dana-Farber Cancer Institute;Eli Lilly | Discontinued |
| PD-1 | Nivolumab | Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Barbara Ann Karmanos Cancer Institute;Bavarian Nordic;Big Ten Cancer Research Consortium;Bristol-Myers Squibb;Canadian Cancer Trials Group;Celleron Therapeutics;Clatterbridge Cancer Centre NHS Foundation Trust;Clovis Oncology;Curie Institute;Daiichi Sankyo Company;Dana-Farber Cancer Institute;Duke University Medical Center;Eisai Inc;Eli Lilly;Emory University;European Thoracic Oncology Platform;Exelixis;Frontier Science foundation;Grupo Espanol Multidisciplinar de Melanoma;H. Lee Moffitt Cancer Center and Research Institute;Hellenic Genitourinary Cancer Group;Hoosier Cancer Research Network;HOVON Foundation;Incyte Corporation;Intergroupe Francophone de Cancerologie Thoracique;Janssen Biotech;Janssen Research & Development;Kansai Medical University;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medarex;Nantes University Hospital;National Cancer Center (Tokyo);National Cancer Centre (Singapore);National Cancer Institute (USA);Nektar Therapeutics;Neon Therapeutics;Netherlands Cancer Institute;Northwestern University;Ono Pharmaceutical;Pharmacyclics;PrECOG;Seattle Genetics;Sidney Kimmel Cancer Center;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syneos Health;The University of Montreal Hospital Research Center;UNICANCER;University College London;University of Liverpool;University of Pittsburgh;University of Texas M. D. Anderson Cancer Center;Vanderbilt-Ingram Cancer Center;Zucero Therapeutics | Approved |
| PD-1 | Nofazinlimab | Cstone Pharmaceuticals | Phase 3 |
| PD-1 | Pembrolizumab | Aduro BioTech;AIO Studien gGmbH;Amgen;Augusta University;Bayer;BerGenBio;Big Ten Cancer Research Consortium;BioLineRx;Canadian Cancer Trials Group;Celgene Corporation;Columbia University;Dana-Farber Cancer Institute;DNAtrix;Duke University;Eisai Co Ltd;Eli Lilly;Emory University;Fox Chase Cancer Center;Genexine;Gilead Sciences;H. Lee Moffitt Cancer Center and Research Institute;Hoosier Cancer Research Network;Icahn School of Medicine at Mount Sinai;ImmunoGen;Incyte Corporation;Institut fuer Frauengesundheit;Institute of Cancer Research;M. D. Anderson Cancer Center;Massachusetts General Hospital;Mayo Clinic;Memorial Sloan-Kettering Cancer Center;Merck & Co;Merck Sharp & Dohme;National Cancer Center Hospital East;National Cancer Institute (France);National Cancer Institute (USA);Netherlands Cancer Institute;Northwestern University;NYU Langone Medical Center;Oslo University Hospital;Plexxikon;Providence Health & Services;Royal Marsden NHS Foundation Trust;Sarcoma Alliance for Research through Collaboration;Sellas Life Sciences Group;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Spanish Breast Cancer Research Group;Syndax Pharmaceuticals;TG Therapeutics Inc;University Health Network;University of Alabama;University of Birmingham;University of California at Los Angeles;University of California at San Francisco;University of California San Diego;University of Colorado at Denver;University of Miami;University of Pittsburgh;University of Utah;University of Washington;Verastem Oncology;Wakayama Medical University;Washington University School of Medicine;Yale University;The Leukemia & Lymphoma Society | Approved |
| PD-1 | Pidilizumab | American Cancer Society;Beth Israel Deaconess Medical Center;CureTech;Georgia Regents University;Hadassah Medical Organization;Northwestern University;The Ohio State University Comprehensive Cancer Center;University of Texas M. D. Anderson Cancer Center | Approved |
| PD-1 | Pimivalimab | Jounce Therapeutics | Approved |
| PD-1 | Pradusinstobart | MD Anderson Cancer Center;Lyvgen Biopharma | Approved |
| PD-1 | Prolgolimab | Biocad | Approved |
| PD-1 | Pucotenlimab | Taizhou Hanzhong Pharmaceuticals | Approved |
| PD-1 | Retifanlimab | MacroGenics;Incyte Corporation;ZAI Lab | Approved |
| PD-1 | Rulonilimab | Shandong New Time Pharmaceutical Co., LTD | Phase 2/3 |
| PD-1 | Sasanlimab | Pfizer | Phase 3 |
| PD-1 | Serplulimab | Henlix Biotech;Shanghai Henlius Biotech | Approved |
| PD-1 | Sintilimab | Adimab;Innovent Biologics;Jiangsu Provincial Peoples Hospital;Sun Yat-Sen University | Approved |
| PD-1 | Spartalizumab | Asan Medical Center;Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Palobiofarma;Seoul National University Hospital | Approved |
| PD-1 | Tislelizumab | BeiGene;Celgene Corporation | Approved |
| PD-1 | Toripalimab | Fudan University;Peking University;Shanghai Junshi Biosciences;Sun Yat-Sen University | Approved |
| PD-1 | Zimberelimab | Harbin Gloria Pharmaceuticals;WuXi Biologics;Arcus Biosciences;Beijing Cancer Hospital;Guangzhou Gloria Biosciences;Strata Oncology | Approved |
| PD-1 x CTLA-4 | Vudalimab | Xencor | Approved |
| PD-1, VEGF | Ivonescimab | Akesobio Australia Pty Ltd | Phase 3 |
| PD-L1 | Adebrelimab | Jiangsu Hengrui Medicine;Atridia | Approved |
| PD-L1 | Atezolizumab | Amgen;ARCAGY/GINECO Group;BioLineRx;Chugai Pharmaceutical;Clovis Oncology;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;Exelixis;Fondazione Michelangelo;GEICO (Spanish Ovarian Cancer Research Group);Genentech;GERCOR;Gradalis;H. Lee Moffitt Cancer Center and Research Institute;Immune Design;Incyte Corporation;Johns Hopkins University;Kaiser Permanente;M. D. Anderson Cancer Center;Memorial Sloan-Kettering Cancer Center;National Cancer Center (Korea);National Cancer Institute (USA);Netherlands Cancer Institute;Roche;Sanofi;Seattle Genetics;University Hospital Southampton NHS Foundation Trust;University Medical Center Groningen;University of California;University of California at San Francisco;University of Oklahoma;Yale University | Approved |
| PD-L1 | Avelumab | AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine | Approved |
| PD-L1 | Cosibelimab | Approved | |
| PD-L1 | Durvalumab | Advaxis;AIO Studien gGmbH;AstraZeneca;Big Ten Cancer Research Consortium;Canadian Cancer Trials Group;Case Comprehensive Cancer Center;Celgene International SARL;Centre hospitalier de l'Universite de Montreal;Centre Leon Berard;Charite - Universitatsmedizin Berlin;Childrens Hospital Los Angeles;Dana-Farber Cancer Institute;Eli Lilly;Fondazione IRCCS Istituto Nazionale dei Tumori;GlaxoSmithKline;Gradalis;Grand Hopital de Charleroi;Grupo Espanol de Tumores Neuroendocrinos;Gustave Roussy;Immunocore;Innate Pharma;Institut Claudius Regaud;Juno Therapeutics;Kyoto Breast Cancer Research Network;Ludwig Institute for Cancer Research;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;Mirati Therapeutics;Myriad Genetic Laboratories;National Cancer Institute (USA);National Health and Medical Research Council;Northwestern University;Pharmacyclics;Plexxikon;Radboud University;Samsung Medical Center;Spanish Oncology Genito-Urinary Group;Swiss Group for Clinical Cancer Research;UNC Lineberger Comprehensive Cancer Center;UNICANCER;University College London;University of Colorado at Denver;University of Kansas Medical Center;University of Maryland Greenbaum Cancer Center;University of Southern California;University of Sydney;University of Texas M. D. Anderson Cancer Center;VentiRx Pharmaceuticals;Washington University School of Medicine;Yale University;Yonsei University College of Medicine | Approved |
| PD-L1 | Sugemalimab | Cstone Pharmaceuticals | Approved |
| PD-L1 | CBT Pharmaceuticals, Inc | Phase 3 | |
| PD-L1, CTLA-4 | Erfonrilimab | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 3 |
| PD-L1, TGF-β | Retlirafusp alfa | Jiangsu HengRui Medicine Co., Ltd. | Phase 2/3 and Phase 3 |
| PD-L1, VEGF | Biotheus Inc. | Phase 2/3 | |
| PDGFRA | Olaratumab | ImClone Systems;Eli Lilly;Institute for Clinical Oncological Research | Approved |
| PDGFRB | Rinucumab | Regeneron Pharmaceuticals | Discontinued |
| phosphatidylserine | Bavituximab | Avid Bioservices;IMV;Massachusetts General Hospital;Merck Sharp & Dohme;Peregrine Pharmaceuticals;University of Arizona;University of Texas Southwestern Medical Center;University of Texas M. D. Anderson Cancer Center | Approved |
| PMSA | Rosopatamab | Weill Cornell Medical, Telix Pharmaceuticals | Approved |
| PRLR | Rolinsatamab | AbbVie | Approved |
| pro-GDF-8 | Apitegromab | Scholar Rock | Approved |
| Protein substitute | Valziflocept | #N/A | #N/A |
| PTK7 | Cofetuzumab | Stemcentrx;Indiana University;Pfizer;Stemcentrx | Approved |
| PTPRC | Iodine (131I) apamistamab | #N/A | #N/A |
| PVRL4 | Enfortumab vedotin | #N/A | #N/A |
| Rabies virus spike glycoprotein | Zamerovimab, mazorelvimab | Synermore Biologics Co. Ltd. | Phase 3 |
| RABV | Foravirumab | Crucell;Sanofi Pasteur | Discontinued |
| RABV | Rafivirumab | Crucell;Sanofi Pasteur | Discontinued |
| RANKL | Denosumab | Amgen;Daiichi Sankyo Company;European Thoracic Oncology Platform;GlaxoSmithKline;Jules Bordet Institute;Melbourne Health;University Health Network | Approved |
| RGMA | Elezanumab | AbbVie | Approved |
| RHD | Roledumab | LFB Biotechnologies | Approved |
| ROR1 | Zilovertamab | University of California;Oncternal Therapeutics;Merck | Approved |
| ROR2 | Ozuriftamab | BioAtla | Approved |
| RSPO3 | Rosmantuzumab | OncoMed Pharmaceuticals | Discontinued |
| RSV | Clesrovimab | Merck Sharp & Dohme Corp. | Phase 2/3 and Phase 3 |
| RSV | Gontivimab | Ablynx | Discontinued |
| RSV | Motavizumab | MedImmune | Discontinued |
| RSV | Nirsevimab | AIMM Therapeutics;MedImmune | Approved |
| RSV | Palivizumab | Approved | |
| RSV | Suptavumab | Regeneron Pharmaceuticals | Discontinued |
| RTN4 | Atinumab | Novartis | Discontinued |
| RTN4 | Ozanezumab | GlaxoSmithKline | Discontinued |
| S. aureus alpha toxin | Suvratoxumab | Biosynexus;GlaxoSmithKline;Regeneron Pharmaceuticals;MedImmune | Approved |
| S. aureus ?-toxin | Tosatoxumab | Aridis Pharmaceuticals;Kenta Biotech | Approved |
| SAA1 | Birtamimab | Neotope Biosciences;Onclave Therapeutics;Prothena | Discontinued |
| SARS-CoV-2 | Bamlanivimab | Abcellera;Eli Lilly and Company;National Institute of Allergy and Infectious Diseases | Approved |
| SARS-CoV-2 | Casirivimab + imdevimab | Approved | |
| SARS-CoV-2 | Enuzovimab | ABL Bio;HiFiBiO Therapeutics | Approved |
| SARS-CoV-2 | Regdanvimab | Approved | |
| SARS-CoV-2 | Sotrovimab | Approved | |
| SARS-CoV-2 | Tixagevimab, cilgavimab | Approved | |
| SARS-CoV-2 | AstraZeneca | Phase 3 | |
| SDC1 | Indatuximab | Biotest AG | Discontinued |
| SELP | Crizanlizumab | Selexys Pharmaceuticals;Novartis | Approved |
| SELP | Inclacumab | Genmab;Roche;Global Blood Therapeutics | Discontinued |
| SELP | Torapsel | #N/A | #N/A |
| SEMA4D | Pepinemab | Bristol-Myers Squibb;Children's Oncology Group;Emory University;Merck KGaA;National Cancer Institute (USA);Teva Pharmaceutical Industries;UCLAs Jonsson Comprehensive Cancer Center;Vaccinex | Approved |
| serotype IATS O11 | Panobacumab | Berna Biotech;Aridis Pharmaceuticals | Approved |
| shiga toxin type 1 | Pritoxaximab | Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc | Discontinued |
| shiga toxin type 2 | Setoxaximab | Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc | Discontinued |
| SLAMF7 | Azintuxizumab | AbbVie | Discontinued |
| SLAMF7 | Elotuzumab | AbbVie;Australasian Leukaemia & Lymphoma Group;Bristol-Myers Squibb;PDL BioPharma | |
| SLC29A2 | Clervonafusp alfa | #N/A | #N/A |
| SLC34A2 | Lifastuzumab vedotin | #N/A | #N/A |
| SLC39A6 | Ladiratuzumab | Merck & Co;Quantum Leap Healthcare Collaborative;Seattle Genetics | Approved |
| SLITRK6 | Sirtratumab | Astellas/Agensys;Seattle Genetics | Approved |
| SNCA | Cinpanemab | Neurimmune Therapeutics;Biogen | Discontinued |
| SNCA | Exidavnemab | AbbVie | Approved |
| SNCA | Prasinezumab | Neotope Biosciences;Chugai Pharmaceutical;Prothena;Roche | Approved |
| Sortilin | Latozinemab | Alector | Phase 3 |
| SOST | Blosozumab | Eli Lilly | Approved |
| SOST | Resugobart | TBC | Approved |
| SOST | Romosozumab | ChiroscienceGroup plc;Amgen;UCB | |
| SOST | Setrusumab | MorphoSys;Novartis;Mereo BioPharma;Ultragenyx Pharmaceutical Inc | Approved |
| STAB1 | Bexmarilimab | Faron Pharmaceuticals | Approved |
| STEAP1 | Vandortuzumab vedotin | #N/A | #N/A |
| TACSTD2 | Sacituzumab | IBC Pharmaceuticals;Immunomedics;University of Wisconsin Comprehensive Cancer Center;Yale University | Approved |
| Tau | Eisai Co., Ltd. | Phase 2/3 | |
| Tetanus toxin | Zhuhai Trinomab Biotechnology Co Ltd. | Phase 3 | |
| TFPI | Befovacimab | na | Approved |
| TFPI | Concizumab | Novo Nordisk | Approved |
| TFRC | Pabinafusp alfa | #N/A | #N/A |
| TGFB1 | Lerdelimumab | Cambridge Antibody Technology | Discontinued |
| TGFB1 | Linavonkibart | Scholar Rock | Approved |
| TGFB1 | Metelimumab | Cambridge Antibody Technology | Discontinued |
| TGFbeta | Fresolimumab | Cambridge Antibody Technology;Baylor College of Medicine;Genzyme Corporation;Sanofi Genzyme | Discontinued |
| TGM2 | Zampilimab | UCB | Approved |
| Ticagrelor | Bentracimab | AstraZeneca | Phase 3 |
| TIGIT | Domvanalimab | Arcus Biosciences | Phase 3 |
| TIGIT | Etigilimab | OncoMed Pharmaceuticals | Approved |
| TIGIT | Ociperlimab | BeiGene | Phase 3 |
| TIGIT | Tamgiblimab | Innovent Biologics | Approved |
| TIGIT | Tiragolumab | Genentech | Phase 3 |
| TIGIT | Vibostolimab | Merck Sharp & Dohme Corp. | Phase 3 |
| TIM-3 | Sabatolimab | Novartis | Phase 3 |
| Tissue factor pathway inhibitor | Concizumab | Approved | |
| Tissue factor pathway inhibitor | Marstacimab | Pfizer | Phase 3 |
| TLR2 | Tomaralimab | Opsona Therapeutics | Approved |
| TNC | Tenatumomab | sigma-tau SpA | Discontinued |
| TNF | Adalimumab | Abbvie;MedImmune;180 Life Sciences | Approved |
| TNF | Adalimumab beta | #N/A | #N/A |
| TNF | Certolizumab pegol | Approved | |
| TNF | Etanercept | #N/A | #N/A |
| TNF | Golimumab | Approved | |
| TNF | Infliximab | Centocor;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;National Jewish Medical and Research Center;Xian-Janssen | |
| TNF | Lenercept | #N/A | #N/A |
| TNF | Onercept | #N/A | #N/A |
| TNF | Opinercept | #N/A | #N/A |
| TNF | Ozoralizumab | Ablynx;Eddingpharm;Pfizer;Taisho Pharmaceutical | Approved |
| TNF | Pegsunercept | #N/A | #N/A |
| TNF | Placulumab | Domantis;Peptech;Arana Therapeutics;Teva Pharmaceutical Industries | Discontinued |
| TNF | Remtolumab | Abbott Laboratories;Abbvie | Discontinued |
| TNF | Tulinercept | #N/A | #N/A |
| TNF-α receptor I | Tanfanercept | #N/A | #N/A |
| TNFRSF10B | Benufutamab | Genmab;VU University Medical Center;iDD Biotech | Approved |
| TNFRSF10B | Conatumumab | Amgen;Takeda | Discontinued |
| TNFRSF10B | Drozitumab | Genentech | Discontinued |
| TNFRSF10B | Lexatumumab | Cambridge Antibody Technology;Human Genome Sciences | Discontinued |
| TNFRSF10B | Tigatuzumab | Daiichi Sankyo Company;University of Alabama at Birmingham | Discontinued |
| TNFRSF10B | Tilogotamab | Genmab | Approved |
| TNFRSF12A | Enavatuzumab | PDL BioPharma;Abbott Laboratories | Discontinued |
| TNFRSF17 | Ciltacabtagene autoleucel | #N/A | #N/A |
| TNFRSF17 | Orvacabtagene autoleucel | #N/A | #N/A |
| TNFRSF17;CD3E | Vonsetamig | TBC | Approved |
| TNFRSF4 | Cudarolimab | Innovent Biologics | Discontinued |
| TNFRSF4 | Revdofilimab | AbbVie | Approved |
| TNFRSF4 | Tavolimab | European Network of Gynaecological Oncological Trial Groups;MedImmune | Discontinued |
| TNFRSF4 | Telazorlimab | Glenmark Pharmaceuticals | Approved |
| TNFRSF4 | Vonlerolizumab | Genentech | Discontinued |
| TNFRSF9 | Evunzekibart | Alligator Bioscience | Approved |
| TNFSF11 | Narlumosbart | CSPC Pharmaceutical Group;Shanghai Jinmante Biotechnology | Approved |
| TNFSF13 | Atacicept | #N/A | #N/A |
| TNFSF13B | Belimumab | Assistance Publique Hopitaux de Paris;Cancer Trials Australia;GlaxoSmithKline;Hospital for Special Surgery;Human Genome Sciences;North Shore-Long Island Jewish Health System;University of Alabama at Birmingham;University of Pennsylvania;University of Wisconsin-Madison;Washington University School of Medicine;Cambridge Antibody Technology | Approved |
| TNFSF13B | Blisibimod | #N/A | #N/A |
| TNFSF13B | Briobacept | #N/A | #N/A |
| TNFSF13B | Telitacicept | #N/A | #N/A |
| TNFSF14 | Quisovalimab | Avalo Therapeutics | Approved |
| TNFSF4 | Amlitelimab | Kymab | Approved |
| Toll-like receptor 4 | Paridiprubart | NovImmune SA | Phase 2/3 |
| toxin A | Actoxumab | Bristol-Myers Squibb;Merck;University of Massachussets Medical School | Discontinued |
| TPBG | Naptumomab estafenatox | #N/A | #N/A |
| Trop-2 | Datopotamab deruxtecan | Daiichi-Sankyo | Phase 3 |
| Trop-2 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Phase 3 | |
| TSLP | Tezepelumab | Amgen;AstraZeneca;Bispebjerg Hospital;Lund University;MedImmune;University of Copenhagen;University of Newcastle in Australia | Approved |
| TYRP1 | Flanvotumab | ImClone Systems;Eli Lilly | Discontinued |
| VEGF | Aflibercept | #N/A | #N/A |
| VEGF | Ranibizumab | Genentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn | Approved |
| VEGF | Suvemcitug | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 3 |
| VEGF | Bio-Thera Solutions | Phase 3 | |
| VEGF | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2/3 | |
| VEGF | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd | Phase 3 | |
| VEGFA | Abicipar pegol | #N/A | #N/A |
| VEGFA | Bevacizumab | All Ireland Cooperative Oncology Research Group;ARCAGY/GINECO Group;Austrian Breast & Colorectal Cancer Study Group;Bayer;Beth Israel Deaconess Medical Center;Breast Cancer Research Foundation;Brigham and Women's Hospital;Bristol-Myers Squibb;Cancer and Leukemia Group B;Cancer Research UK;Chugai Pharmaceutical;Cincinnati Children's Hospital Medical Center;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;European Thoracic Oncology Platform;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Indiana University School of Medicine;Japan Breast Cancer Research Group;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medical University of South Carolina;Melanoma Research Foundation Breakthrough Consortium;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National Comprehensive Cancer Network;NCIC Clinical Trials Group;North Central Cancer Treatment Group;NSABP Foundation;Ohio State University Medical Center;Peter MacCallum Cancer Centre;Roche;Royal Marsden NHS Foundation Trust;Sanofi;Sarcoma Alliance for Research through Collaboration;SCRI Development Innovations;South Eastern European Research Oncology Group;Spanish Cooperative Group for Digestive Tumour Therapy;Spanish Lung Cancer Group;Stanford University School of Medicine;SWOG;The Catalan Institute of Oncology;UNICANCER;University College London;University of Alabama at Birmingham;University of Arkansas System;University of California Davis;University of Iowa;University of Oklahoma;University of Tennessee;University of Texas M. D. Anderson Cancer Center;US Oncology Research;West German Study Group;Xijing Hospital | Approved |
| VEGFA | Brolucizumab | ESBATech;Alcon | Approved |
| VEGFA | Conbercept | #N/A | #N/A |
| VEGFA | Dilpacimab | AbbVie | Approved |
| VEGFA | Faricimab | Chugai Pharmaceutical;Roche | Approved |
| VEGFA | Vanucizumab | Roche | Discontinued |
| VEGFA | Varisacumab | Peregrine Pharmaceuticals;University of Texas Southwestern Medical Center;Affitech Research AS | Discontinued |
| VEGFR2 | Ramucirumab | Dyax;AstraZeneca;Dana-Farber Cancer Institute;Eli Lilly;Merck Sharp & Dohme;University of Texas M. D. Anderson Cancer Center;Washington University School of Medicine | Approved |
| VEGFR2 | GeneScience Pharmaceuticals Co., Ltd. | Phase 3 | |
| VIM | Burfiralimab | ImmuneMed | Approved |
| VISTA | Onvatilimab | Janssen Research & Development | Approved |
| VWF | Caplacizumab | Ablynx | |
| Wnt ligands In the Wnt/Frizzled pathway | Ipafricept | #N/A | #N/A |
| Zaire Ebola virus | Atoltivimab | Regeneron Pharmaceuticals | Discontinued |
| Zaire Ebola virus | Cosfroviximab | Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases | Approved |
| Zaire Ebola virus | Larcaviximab | Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases | Approved |
| Zaire Ebola virus | Maftivimab | Regeneron Pharmaceuticals | Discontinued |
| Zaire Ebola virus | Odesivimab | Regeneron Pharmaceuticals | Approved |
| Zaire Ebola virus | Porgaviximab | Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases | Discontinued |
| α4β7 integrin | Vedolizumab | Medical College of Wisconsin;Millennium Pharmaceuticals;Takeda;Takeda Oncology | Approved |